Cancer-Testis Antigens as New Candidate Diagnostic Biomarkers for Transitional Cell Carcinoma of Bladder
- 201 Downloads
To evaluate the diagnostic potential of 23 candidate genes, belonging to a category of tumor-specific antigens known as cancer-testis antigens (CTAs), in transitional cell carcinoma (TCC) patients. The expression of 16 known candidate CTAs and seven testis restricted/selective genes, predominantly expressed in the testis, was evaluated by reverse transcriptase-polymerase chain reaction (RT-PCR). Urinary exfoliated cells (UECs) and cancerous tissues of 73 TCC patients were used as cases, while 25 tumor-free adjacent bladder tissue specimens along with bladder tissue specimens and UECs of five non-TCC individuals were analyzed as controls. Among the known CTAs only MAGEA3, MAGEB4, TSGA10, PIWIL2, OIP5, and ODF4 were expressed specifically in TCC tissues and UEC samples. ACTL7A, AURKC, and CGB2 were testis-restricted/selective genes that indicated specific expression in cases in comparison to controls. MAGEA3, MAGEB4, and ODF4 mRNA was detectable in more than 50% of both TCC tissues, and UEC samples. Slight differences were detected in the mRNA expression pattern of candidate genes between the UEC samples and tumor tissues. Different panels formed by combinations of these genes can show up to 95.9% and 94.5% of positivity in TCC tissues and UEC samples, respectively, suggesting their diagnostic and surveillance potential. Meanwhile the RT-PCR assay of at least MAGEA3, MAGEB4, and ODF4 may be particularly useful for diagnostic and surveillance of TCC in the form of a multi-biomarker panel.
KeywordsCancer testis antigen Clinical markers Transitional cell carcinoma Urinary bladder neoplasms
Sincere gratitude and appreciation to Dr. R Glen Calderhead who thoroughly copyedited our manuscript for language usage, spelling, and grammar. We are also thankful to Mrs. Harieh Rasouli, Mrs. Soheila Khamseh, Mr. Esmaeel Khoshbakht, and Mr. Saeed Farabi who kindly helped us during the sampling process.
The research reported in this manuscript has been fully funded by the Cancer Research Center of Tehran Medical Sciences University under reference number 93–03–51-23,968 and supported by the Uro Oncology Research Center of Tehran Medical Sciences University in the terms of sampling.
- 3.Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BWG, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M (2013) EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4):639–653. https://doi.org/10.1016/j.eururo.2013.06.003 CrossRefGoogle Scholar
- 5.Turco P, Houssami N, Bulgaresi P, Troni GM, Galanti L, Cariaggi MP, Cifarelli P, Crocetti E, Ciatto S (2011) Is conventional urinary cytology still reliable for diagnosis of primary bladder carcinoma? Accuracy based on data linkage of a consecutive clinical series and cancer registry. Acta Cytol 55(2):193–196. https://doi.org/10.1159/000320861 CrossRefGoogle Scholar
- 9.Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4:1Google Scholar
- 11.Zamuner FT, Karia BT, de Oliveira CZ, Santos CR, Carvalho AL, Vettore AL (2015) A comprehensive expression analysis of cancer testis antigens in head and neck squamous cell carcinoma revels MAGEA3/6 as a marker for recurrence. Mol Cancer Ther 14(3):828–834. https://doi.org/10.1158/1535–7163.mct-14-0796 CrossRefGoogle Scholar
- 12.Bellati F, Napoletano C, Tarquini E, Palaia I, Landi R, Manci N, Spagnoli G, Rughetti A, Panici PB, Nuti M (2007) Cancer testis antigen expression in primary and recurrent vulvar cancer: association with prognostic factors. Eur J Cancer 43(17):2621–2627. https://doi.org/10.1016/j.ejca.2007.08.031 CrossRefGoogle Scholar
- 14.Fradet Y, Picard V, Bergeron A, LaRue H (2005) Cancer-testis antigen expression in bladder cancer. Prog Urol 15(6 Suppl 1):1303–1313Google Scholar
- 20.Kawai T, Enomoto Y, Morikawa T, Matsushita H, Kume H, Fukayama M, Yamaguchi H, Kakimi K, Homma Y (2014) High expression of heat shock protein 105 predicts a favorable prognosis for patients with urinary bladder cancer treated with radical cystectomy. Mol Clin Oncol 2(1):38–42. https://doi.org/10.3892/mco.2013.203 CrossRefGoogle Scholar
- 21.Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, Lehvaslaiho M, Carninci P, Hayashizaki Y, Jongeneel CV, Simpson AJ, Old LJ, Hide W (2008) Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A 105(51):20422–20427. https://doi.org/10.1073/pnas.0810777105 CrossRefGoogle Scholar
- 22.Eble J, Sauter G, Epstein J, Sesterhenn I (2004) World Health Organization classification of tumors. Tumors of the urinary system and genital organs. IARC Press, Lyon, Pathology and GeneticsGoogle Scholar